Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118281 · ClinicalTrials.gov registry record · Phase 3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
A Phase 3 study of Cardiovascular Risk and Acute Myocardial Infarction (AMI), sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 10,000
- Enrollment target
- 20
- Study locations
NCT06118281: Recruiting Phase 3 study of Cardiovascular Risk and Acute Myocardial Infarction (AMI), sponsored by Novo Nordisk A/S.
NCT06118281 is a Phase 3 study of Cardiovascular Risk and Acute Myocardial Infarction (AMI) that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 10,000 participants, above the 5,168-participant average among 5 other Cardiovascular Risk trials with a reported enrollment target (93% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06118281, a Phase 3 study of Cardiovascular Risk and Acute Myocardial Infarction (AMI), is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.
Primary Outcome
Measured in months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ziltivekimab
Study Locations (20)
California
- Valley Clinical Trials - Covina
- Valley Clinical Trials - Covina
- UCSD Medical Center - La Jolla
- Loma Linda University Faculty Medical Clinics - Loma Linda
- VAGrtrLosAngelesHlthcareSystem - Los Angeles
- University of Californ LA-UCLA - Los Angeles
- University Of California Irvine - Orange
- Kaiser Permanente Viewridge Medical Offices - San Diego
- San Diego Cardiac Center - San Diego
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- Birmingham VA Medical Center - Birmingham
- Grandview Medical Center - Birmingham
- Eastern Shore Rsrch Inst, LLC - Fairhope
- Heart Center Rsrch_Hunstville - Huntsville
- Mobile Heart USA Health Cardiology Clinic - Mobile
Arizona
- Mercy Gilbert Medical Center - Gilbert
- Mayo Clinic Arizona - Phoenix
- Honor Health - Scottsdale
Arkansas
- Arkansas Cardiology Clinic - Little Rock
- Central Arkansas Veteran's Healthcare System - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2026-09-03 |
| Phase | Phase 3 |
What NCT06118281 shows while recruiting
NCT06118281 is an interventional study that assigns participants to a tested intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 5,168-participant average among 5 other Cardiovascular Risk trials with a reported enrollment target (93% higher).
The record links to 2 conditions, with Cardiovascular Risk appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06118281 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06118281 about?
NCT06118281 is a clinical study titled "ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack". The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medi...
What is the current status of trial NCT06118281?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 10,000 participants. The study started on 2024-06-25. Estimated completion is 2026-09-03.
What conditions does trial NCT06118281 study?
This clinical trial studies the following conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI).
What interventions are being tested in trial NCT06118281?
The interventions under investigation include: Placebo (DRUG), Ziltivekimab (DRUG).
Who is sponsoring clinical trial NCT06118281?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118281 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
-
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
Dose-Response to Resistance Exercise on Cardiovascular Health
RECRUITING · NA
-
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI